Tumor mutational burden quantification from targeted gene panels: major advancements and challenges
L Fancello, S Gandini, PG Pelicci… - Journal for immunotherapy …, 2019 - Springer
Tumor mutational burden (TMB), the total number of somatic coding mutations in a tumor, is
emerging as a promising biomarker for immunotherapy response in cancer patients. TMB …
emerging as a promising biomarker for immunotherapy response in cancer patients. TMB …
Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction
Immunotherapy, represented by immune checkpoint inhibitors (ICI), is transforming the
treatment of cancer. However, only a small percentage of patients show response to ICI, and …
treatment of cancer. However, only a small percentage of patients show response to ICI, and …
[HTML][HTML] European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment
AJ Stratigos, C Garbe, C Dessinioti, C Lebbe… - European Journal of …, 2020 - Elsevier
In order to update recommendations on treatment, supportive care, education and follow-up
of patients with invasive cutaneous squamous cell carcinoma (cSCC), a multidisciplinary …
of patients with invasive cutaneous squamous cell carcinoma (cSCC), a multidisciplinary …
Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies
A Necchi, D Raggi, A Gallina, R Madison, M Colecchia… - European urology, 2020 - Elsevier
Background Patients with predominant variant histology (VH) of bladder tumors, defined as
involving> 50% of the tumor specimens, are typically excluded from clinical trials, and for …
involving> 50% of the tumor specimens, are typically excluded from clinical trials, and for …
Crosstalk between the MSI status and tumor microenvironment in colorectal cancer
Colorectal cancer (CRC) patients, especially those with deficient mismatch repair
(dMMR)/microsatellite instability-high (MSI-H) tumors, whose sensitivity to immune …
(dMMR)/microsatellite instability-high (MSI-H) tumors, whose sensitivity to immune …
Precision medicine in non-small cell lung cancer: Current applications and future directions
Advances in biomarkers, targeted therapies, and immuno-oncology have transformed the
clinical management of patients with advanced NSCLC. For oncogene-driven tumors, there …
clinical management of patients with advanced NSCLC. For oncogene-driven tumors, there …
CD4 and CD8 T lymphocyte interplay in controlling tumor growth
D Ostroumov, N Fekete-Drimusz, M Saborowski… - Cellular and molecular …, 2018 - Springer
The outstanding clinical success of immune checkpoint blockade has revived the interest in
underlying mechanisms of the immune system that are capable of eliminating tumors even …
underlying mechanisms of the immune system that are capable of eliminating tumors even …
Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: a hospital‐based study
K Sunami, H Ichikawa, T Kubo, M Kato… - Cancer …, 2019 - Wiley Online Library
Next‐generation sequencing (NGS) of tumor tissue (ie, clinical sequencing) can guide
clinical management by providing information about actionable gene aberrations that have …
clinical management by providing information about actionable gene aberrations that have …
Microsatellite instability status determined by next‐generation sequencing and compared with PD‐L1 and tumor mutational burden in 11,348 patients
A Vanderwalde, D Spetzler, N Xiao, Z Gatalica… - Cancer …, 2018 - Wiley Online Library
Microsatellite instability (MSI) testing identifies patients who may benefit from immune
checkpoint inhibitors. We developed an MSI assay that uses data from a commercially …
checkpoint inhibitors. We developed an MSI assay that uses data from a commercially …